Manchester is home to several cancer prevention centres and some largescale studies evaluating new screening procedures.
The Genesis Breast Cancer Prevention Centre
The Genesis Breast Cancer Prevention Centre is the first purpose-built Centre of its kind in Europe. It is home to a team of researchers whose aim is to tackle the problem of breast cancer through research into prevention, early diagnosis and screening. It has the largest Family History Clinic in Europe for women with breast cancer in the family.
The purpose-built Centre was launched at The University Hospital of South Manchester NHS Foundation Trust in 2007 and:
- Conducts clinical research
- Hosts the UK’s largest family history clinic
- Trains specialists in all breast cancer disciplines
- Promotes breast screening and early diagnosis
- Researches new treatments to stop breast cancer in its early stages
For more information on the Centre, download the overview document and visit the website.
The PROCAS study aims to predict breast cancer risk for women who attend routine NHS breast screening in Greater Manchester. A woman’s risk will be assessed by collecting extra information on each of the most important breast cancer risk factors – family history, lifestyle factors, breast density and genetics.
Each woman will be asked to complete a short and simple questionnaire that asks about family history and lifestyle factors. Extra assessments will also be carried out on the mammogram, to calculate how dense the breasts are. Women will be seen at their routine mammogram appointment, so participation in the study does not require any extra visits.
For more on the PROCAS study, click here or go to our annual report to learn about one woman who did not know she had breast cancer until she took part in the study.
Ovarian cancer is the leading cause of death from gynaecological cancers in the United Kingdom. Majority of the women are diagnosed with bulky disease that has spread beyond the ovary and 60% die within five years of diagnosis.
This has led to efforts to try and detect the disease earlier before it has spread. The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) aims to answer the question as to whether screening can save lives.
In this trial over 1.2 million women were invited and 202,638, postmenopausal women aged 50 and above were recruited through thirteen centres in England, Wales and Northern Ireland between 2001 and 2005.
They were randomly assigned to two groups – (1) control group (101,359) who received no screening (to reflect the current situation in the UK) and (2) screen group who had annual screening till December 2011.
Read more here